Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Fallopian Tube Neoplasms 8Ovarian Neoplasms 6Neoplasm Metastasis 5Breast Neoplasms 5Prostatic Neoplasms 4Triple Negative Breast Neoplasms 3Glioma 3Endometrial Neoplasms 3Wilms Tumor 2Small Cell Lung Carcinoma 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Pancreatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioblastoma 2Ependymoma 2Cholangiocarcinoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 2Biopsy 2olaparib 1entinostat 1Specimen Handling 1Pharmacogenomic Testing 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1Blood Specimen Collection 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Anatomic Stage III Breast Cancer AJCC v8 × olaparib × Clear all
NCT05967286 2024-03-20

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Withdrawn
Breast

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡